BIM-018
 | |
| Systematic (IUPAC) name | |
|---|---|
|
2-(naphthalene-1-carbonyl)-1-pentyl-1H-1,3-benzodiazole | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| ChemSpider | 29763750 |
| Chemical data | |
| Formula | C23H22N2O |
| Molar mass | 342.4 g/mol |
| |
| |
BIM-018 is a synthetic cannabinoid that is the benzimidazole analog of JWH-018. It is presumed to be a potent agonist of the CB2 receptor and has been sold online as a designer drug.[1]
Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor.[2]
See also
References
- ↑ "BIM-018". Cayman Chemical. Retrieved 24 July 2015.
- ↑ Daniel Pagé, Elise Balaux, Luc Boisvert, Ziping Liu, Claire Milburn, Maxime Tremblay, Zhongyong Wei, Simon Woo, Xuehong Luo, Yun-Xing Cheng, Hua Yang, Sanjay Srivastava, Fei Zhou, William Brown, Miroslaw Tomaszewski, Christopher Walpole, Leila Hodzic, Stéphane St-Onge, Claude Godbout, Dominic Salois, Keymal Payza (July 2008). "Novel benzimidazole derivatives as selective CB2 agonists". Bioorganic & Medicinal Chemistry Letters 18 (13): 3695–3700. doi:10.1016/j.bmcl.2008.05.073. PMID 18522867.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.